Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
22nd December 2020 | Partners L P/Il Bvf | 509,410 | Conversion of derivative | $0.00 | |
22nd December 2020 | Partners L P/Il Bvf | 11,278 | Conversion of derivative | $0.00 | |
22nd December 2020 | Partners L P/Il Bvf | 97,615 | Conversion of derivative | $0.00 | |
22nd December 2020 | Partners L P/Il Bvf | 1,944 | Conversion of derivative | $0.00 | |
22nd December 2020 | Partners L P/Il Bvf | 654,215 | Conversion of derivative | $0.00 | |
22nd December 2020 | Partners L P/Il Bvf | 15,166 | Conversion of derivative | $0.00 | |
17th December 2020 | Capital Management, Llc Aquilo | 250,000 | Open or private sale | $18.81 | $4,703,225.00 |
16th December 2020 | Capital Management, Llc Aquilo | 14,933 | Open or private sale | $18.62 | $278,034.54 |
9th December 2020 | Partners L P/Il Bvf | 166,194 | Open or private sale | $18.00 | $2,991,492.00 |
9th December 2020 | Partners L P/Il Bvf | 239,274 | Open or private sale | $18.00 | $4,306,932.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas.
6th November 2020
6th November 2020
6th November 2020